TEVA - Teva Pharmaceutical Industries Limited
| Previous Close | 17.92 |
| Open | 17.93 |
| Bid | 17.44 x 500 |
| Ask | 17.80 x 1000 |
| Day's Range | 17.29 - 18.03 |
| 52 Week Range | 10.85 - 33.82 |
| Volume | 10,261,466 |
| Avg. Volume | 12,959,883 |
| Market Cap | 18.009B |
| Beta | 1.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -16.26 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.29 |
- American City Business Journals•17 hours ago
Teva, Procter & Gamble to dissolve OTC partnership.
The joint venture called PGY Healthcare sells OTC product in more than 50 countries outside North America. The company will terminate operations on July 1.
- Market Realist•21 hours ago
Jazz Pharmaceuticals’ 2018 Guidance and Analyst Recommendations
Jazz Pharmaceuticals (JAZZ) estimates that in fiscal 2018, its net revenue will be $1.86 billion–$1.93 billion. Its estimated GAAP (generally accepted accounting principles) gross margin is 93% for 2018.
- American City Business Journals•22 hours ago
P&G sales, earnings per share climb
“We delivered modest top- and bottom-line growth in a challenging macro environment in the third quarter,” CEO David Taylor said.
- Business Wire•23 hours ago
Teva and the Procter & Gamble Company Have Agreed to Terminate the PGT Healthcare Partnership
Teva Pharmaceutical Industries [NYSE and TASE: TEVA] has announced that Teva and the Procter & Gamble Company [NYSE: PG] have agreed to terminate the PGT Healthcare partnership that the two companies established in 2011 to market OTC (Over The Counter) medicines. No significant (material) net financial transfer between Teva and P&G will result from the dissolution. PGT Healthcare has grown into a significant presence in over 50 countries, mainly in Europe and Asia, using market-leading brands such as Vick’s and ratiopharm.
- Market Realist•yesterday
Jazz Pharmaceuticals’ Xyrem, Erwinase, and Defitelio
In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $312.5 million compared to $291 million in 4Q16. In fiscal 2017, Xyrem reported revenues of $1.2 billion compared to $1.1 billion in 2016, which reflected a 7% growth on a YoY basis. Xyrem is used for the treatment of cataplexy in narcolepsy and excessive daytime sleepiness in narcolepsy.
- Market Realist•2 days ago
Jazz Pharmaceuticals: How It’s Positioned before 1Q18
In 4Q17, Jazz Pharmaceuticals (JAZZ) generated revenues of $436.4 million compared to $396.6 in 4Q16, which reflected a 10% growth on a YoY (year-over-year) basis and a 6% growth quarter-over-quarter.
- Market Realist•2 days ago
Novartis’s 1Q18 Estimates: Expectations for Sandoz
Sandoz, the generics arm of Novartis (NVS), includes pharmaceuticals and biotechnological active substances in its portfolio. Sandoz is expected to report growth in operating revenue in 1Q18.
- Business Wire•3 days ago
Teva to Present New Data Across Multiple Therapeutic Areas at 70th Annual Meeting of the American Academy of Neurology
Teva Pharmaceutical Industries Ltd. today announced 38 scientific abstracts across five difficult-to-treat disorders of the central nervous system will be presented at the 70th Annual Meeting of the American Academy of Neurology in Los Angeles from April 21-27, 2018.
Market Realist•3 days agoAbbVie’s Imbruvica in 4Q17 and Fiscal 2017
AbbVie’s (ABBV) Imbruvica generated revenue of $708 million in 4Q17 and $511 million in 4Q16, reflecting ~39% growth YoY (year-over-year) and ~3% growth quarter-over-quarter. In 4Q17, in US and international markets, Imbruvica reported revenue of $585 million and $123 million, respectively, reflecting ~35.3% and ~57.8% growth YoY.
- InvestorPlace•3 days ago
Pfizer Inc. Stock Has a Great Storyline That’s Not Panning Out
At first glance, Pfizer Inc. (NYSE:PFE) appears a worthwhile contrarian trade. Additionally, the overall markets have been soft, allowing shrewd investors to pick up PFE stock at a more attractive valuation. As a result, many analysts are questioning whether Pfizer stock, at its present cost, is worth the risk.
- Reuters•5 days ago
Israeli unions warn Teva Pharm over plan to close Ashdod plant
Israel's main labour federation intends to strike or take legal action against Teva Pharmaceutical Industries (TEVA.TA) if the drugmaker does not suspend a decision to close a plant in the port city of Ashdod, it said on Sunday. Debt-laden Teva (TEVA.N), the world's largest generic drugmaker and Israel's biggest company, said last week that it would close the unprofitable plant in March 2019 after failing to find a buyer for the facility. In a letter to Teva's management, the Histadrut federation said the company's decision was contrary to a previous declaration that it would retain most of its activities in Israel.
- Reuters•5 days ago
Israeli unions warn Teva Pharm over plan to close Ashdod plant
Israel's main labour federation intends to strike or take legal action against Teva Pharmaceutical Industries if the drugmaker does not suspend a decision to close a plant in the port city of Ashdod, it said on Sunday. Debt-laden Teva, the world's largest generic drugmaker and Israel's biggest company, said last week that it would close the unprofitable plant in March 2019 after failing to find a buyer for the facility. In a letter to Teva's management, the Histadrut federation said the company's decision was contrary to a previous declaration that it would retain most of its activities in Israel.
Yahoo Finance Video•13 hours agoMARKETS: Today's winning stocks are more interesting than the losers, like Procter & Gamble
Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.
Yahoo Finance Video•4 days agoMARKETS: These are the top risks CEOs are citing this earnings season
Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.
